PURPOSE: To evaluate the relationship between intracranial hyperpressure (HICP) and mortality in patients with cryptococcal meningitis related to AIDS (CMRA). METHODS: This was an observational retrospective study. Patients were treated according to the Infectious Diseases Society of America recommendations during the evaluation period (days 0, 3, 5 and after hospitalization). High intracranial pressure (HICP) was defined as ICP values of C250 mm H20. The correlation between HICP and mortality at each of the three time points considered was investigated. Statistical analysis on the descriptive parameters and on the probability of a "death" event (odds ratio, OR) at each of those three time points was performed using the statistical software program Epidata. RESULTS: Eighty patients were included in this study, of whom 53 (66.25 %) were male. The average age of the patients was 37.5 ± 8.1 (range 22–55) years. The median CD4?lymphocyte cell count was 35 (range 0–367) cells/ml. Among the entire patient cohort, 53 patients had a favorable outcome, and the mortality rate was 33.75 %. At baseline (day 0), 57 subjects (71.5 %) presented HICP, and these patients had a higher mortality rate than those with a normal ICP, but the difference did not reach statistical significance[OR 1.65, 95 % confidence interval (CI) 0.56–4.84]. On day 3, 41 of the patients presented HICP, and HICP at this timepoint was significantly associated with an increased risk of mortality (OR 4.35, 95 % CI 1.56–12.09). On day 5, 35(43.5 %) patients presented HICP, and HCIP at this time point was also significantly associated with higher mortality (OR 7.23, 95 % CI 2.53–20.14). CONCLUSION: The results of this study confirm an association between HICP and mortality in patients with CMRA and indicate that the control of ICP during the first 5 days of hospitalization is more important than managing HICP only at baseline.
PURPOSE: To evaluate the relationship between intracranial hyperpressure (HICP) and mortality in patients with cryptococcal meningitis related to AIDS (CMRA). METHODS: This was an observational retrospective study. Patients were treated according to the Infectious Diseases Society of America recommendations during the evaluation period (days 0, 3, 5 and after hospitalization). High intracranial pressure (HICP) was defined as ICP values of C250 mm H20. The correlation between HICP and mortality at each of the three time points considered was investigated. Statistical analysis on the descriptive parameters and on the probability of a "death" event (odds ratio, OR) at each of those three time points was performed using the statistical software program Epidata. RESULTS: Eighty patients were included in this study, of whom 53 (66.25 %) were male. The average age of the patients was 37.5 ± 8.1 (range 22–55) years. The median CD4?lymphocyte cell count was 35 (range 0–367) cells/ml. Among the entire patient cohort, 53 patients had a favorable outcome, and the mortality rate was 33.75 %. At baseline (day 0), 57 subjects (71.5 %) presented HICP, and these patients had a higher mortality rate than those with a normal ICP, but the difference did not reach statistical significance[OR 1.65, 95 % confidence interval (CI) 0.56–4.84]. On day 3, 41 of the patients presented HICP, and HICP at this timepoint was significantly associated with an increased risk of mortality (OR 4.35, 95 % CI 1.56–12.09). On day 5, 35(43.5 %) patients presented HICP, and HCIP at this time point was also significantly associated with higher mortality (OR 7.23, 95 % CI 2.53–20.14). CONCLUSION: The results of this study confirm an association between HICP and mortality in patients with CMRA and indicate that the control of ICP during the first 5 days of hospitalization is more important than managing HICP only at baseline.
Authors: Sara A Mirza; Maureen Phelan; David Rimland; Edward Graviss; Richard Hamill; Mary E Brandt; Tracie Gardner; Matthew Sattah; Gabriel Ponce de Leon; Wendy Baughman; Rana A Hajjeh Journal: Clin Infect Dis Date: 2003-02-27 Impact factor: 9.079
Authors: Tihana Bicanic; Annemarie E Brouwer; Graeme Meintjes; Kevin Rebe; Direk Limmathurotsakul; Wirongrong Chierakul; Praprit Teparrakkul; Angela Loyse; Nicholas J White; Robin Wood; Shabbar Jaffar; Thomas Harrison Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: Andrew Kambugu; David B Meya; Joshua Rhein; Meagan O'Brien; Edward N Janoff; Allan R Ronald; Moses R Kamya; Harriet Mayanja-Kizza; Merle A Sande; Paul R Bohjanen; David R Boulware Journal: Clin Infect Dis Date: 2008-06-01 Impact factor: 9.079
Authors: John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: José E Vidal; Juliana Gerhardt; Erique J Peixoto de Miranda; Rafi F Dauar; Gilberto S Oliveira Filho; Augusto C Penalva de Oliveira; David R Boulware Journal: Diagn Microbiol Infect Dis Date: 2012-05 Impact factor: 2.803
Authors: Katherine M Gaskell; Camilla Rothe; Roshina Gnanadurai; Patrick Goodson; Chikondi Jassi; Robert S Heyderman; Theresa J Allain; Thomas S Harrison; David G Lalloo; Derek J Sloan; Nicholas A Feasey Journal: PLoS One Date: 2014-11-06 Impact factor: 3.240
Authors: Matt Douglas-Vail; Taylor Bechamp; Simran Gohal; Robert Soegtrop; Sarah Vitali; Joan Rugemalila; Neil R H Stone Journal: Infect Dis Rep Date: 2015-12-22